Skip to main content

Table 3 PRO response by clinical response* at week 52 (CZP 200 mg plus MTX group, ITT population)

From: Rapid and sustained improvements in health-related quality of life, fatigue, and other patient-reported outcomes in rheumatoid arthritis patients treated with certolizumab pegol plus methotrexate over 1 year: results from the RAPID 1 randomized controlled trial

   ACR20 response by (%)
   SF-36 PCS SF-36 MCS HAQ-DI Pain FAS PtGA
  Clinical response No Yes No Yes No Yes No Yes No Yes No Yes
PRO response No 45.5 14.7 43.4 19.5 44.4 8.7 44.4 3.8 44.1 7.1 86.9 2.0
  Yes 1.0 38.8 3.1 33.9 2.6 44.4 1.0 38.2 2.8 45.9 0 11.1
  Tetrachoric correlation (ASE) 0.9450 (0.0178) 0.8389 (0.0356) 0.9504 (0.0152) 0.9804 (0.0076) 0.9574 (0.0135) 0.9996 (0.0053)
   DAS response by (%)
   SF-36 PCS SF-36 MCS HAQ-DI Pain FAS PtGA
  Clinical response No Yes No Yes No Yes No Yes No Yes No Yes
PRO response No 44.2 16.5 43.2 20.4 43.6 10.0 43.6 5.1 43.9 7.7 44.1 4.9
  Yes 1.0 38.2 2.1 34.4 2.1 44.4 2.1 49.2 1.8 46.7 1.5 49.5
  Tetrachoric correlation (ASE) 0.9344 (0.0204) 0.8674 (0.0322) 0.9496 (0.0156) 0.9776 (0.0085) 0.9672 (0.0114) 0.9833 (0.0069)
  1. *Clinical response = DAS or ACR20 response.
  2. ACR20 = American College of Rheumatology 20% improvement; ASE = asymptomatic standard error; CZP = certolizumab pegol; DAS = disease activity score; FAS = fatigue assessment scale; HAQ-DI = health assessment questionnaire-disability index; ITT = intent to treat; MCS = mental component summary; MTX = methotrexate; PtGA = patient's global assessment; PCS = physical component summary; PRO = patient-reported outcomes; SF-36 = short-form 36-item health survey